Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Alpharadin Stories

2014-04-02 04:21:20

WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo(®) (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC). The randomized, double-blind, placebo-controlled...

2014-01-27 08:27:50

Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE, N.J., Jan. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in...

2013-11-15 04:21:18

WHIPPANY, N.J., Nov. 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo(®) (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) in September of...

2013-09-20 08:25:10

WHIPPANY, N.J., Sept. 20, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo(®) (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The decision of the European Commission on the approval is expected in the second half of 2013. Xofigo...

2013-07-18 08:23:31

-- Significant overall survival benefit observed with radium 223 in patients who received prior treatment with docetaxel and in those who did not -- Radium 223 significantly delayed time to first symptomatic skeletal event -- All main secondary efficacy endpoints with radium 223 were met, showing clinical benefit with radium 223 in patients with castration-resistant prostate cancer and symptomatic...

2013-07-17 16:28:17

WHIPPANY, N.J., July 17, 2013 /PRNewswire/ -- Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo(®) (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM). These data supported the U.S. Food and Drug...

2013-06-27 12:27:26

DUBLIN, June 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/9ksnpc/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017" [http://www.researchandmarkets.com/research/9ksnpc/nuclear ] report...

2013-06-11 23:03:50

Recently approved Xofigo, formally known as Alpharadin, is now available for men with CRPC, and until June 30, 2013 Prostate Cancer Conference attendees can register for a discounted rate. Los Angeles, CA (PRWEB) June 11, 2013 The Prostate Cancer Research Institute announced recent FDA approval of Xofigo (radium 223), and discounted early registration for the 2013 Prostate Cancer Conference until June 30. The recent FDA approval of Xofigo, formally known as Alpharadin, is a new drug for...

2013-05-15 12:34:17

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

2013-02-13 00:20:41

WAYNE, N.J., Feb. 13, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "We are pleased the FDA has granted priority review...